Nyrada, Inc. · ASX:NYR
Nyrada — Shareholder Meeting (November 2023)
18 slides from Nyrada's shareholder meeting presentation, Nov 20, 2023
Slide 1: Annual General Meeting Presentation
For personal use only Annual General Meeting Presentation James Bonnar Chief Executive Officer 20 November 2023│Sydney NSW NYRADA INC (ASX:NYR) 1 AGM PRESENTATION
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer For personal use only This presentation has been prepared by Nyrada Inc (NYR or the Company). It should Although the Company believes that the expectations reflected in the forward-looking not be considered as an offer or invitation to subscribe for, or purchase any sha
Slide 3: Nyrada's Vision, Strategy, and Values
Nyrada’s Vision, Strategy, and Values For personal use only Our vision To become a high-growth pharmaceutical company Better Health Improving patient health is at the heart of specialising in the discovery and Outcomes everything we do. development of novel treatments. We say what we mean and delive
Slide 4: Commercially Focused Business Model with Structural Strengths
Commercially Focused Business Model with Structural Strengths For personal use only We aim to create value for patients and shareholders by advancing optimized, clinic-stage drug candidates towards out-licensing. Lean, scalable Experienced Large molecule Attractive Highly capable team operating gove
Slide 5: Key Programs and Target Markets
Key Programs and Target Markets For personal use only Drug Candidate Indication Aim Target Market (US) Status Neurology Brain Injury First-in-class treatment to prevent >3m Patients / year1 GLP Studies ongoing TRPC 3/6/7 blocker secondary brain injury following Phase I Study: moderate-severe TBI, co
Slide 6: Brain Injury Drug Program
For personal use only Brain Injury Drug Program Novel small molecule TRPC 3/6/7 blocker
Slide 7: Brain Injury Market
Brain Injury Market Population, Problem, Opportunity For personal use only Each year 55 million +12.2 million suffer a stroke4 Each year People are living with the effects of medically assessed TBI3 ~5.5 million One drug class for stroke (tPA) suitable for >15% of patients People suffer a severe TBI
Slide 8: Brain Injury Trajectory, Patient Outcomes, Treatment Aims
Brain Injury Trajectory, Patient Outcomes, Treatment Aims Serial reconstruction from MRI For personal use only Primary Secondary Disability Injury Injury Level 30 mins BECAME STAYED DIED WORSE THE SAME 72 hours IMPROVED Hours Days Weeks Months Reduce secondary injury resulting from TBI or stroke Nyr
Slide 9: Phase I Study Design
Phase I Study Design For personal use only OBJECTIVES To assess the safety, tolerability, and pharmacokinetics of NYR-BI03 DESIGN • Randomised, double-blind placebo – PARTICIPANTS controlled, dose escalation design • Male and female healthy volunteers • 5 cohorts; 8 participants each cohort; • 18 –
Slide 10: Cholesterol Lowering Drug Program
For personal use only Cholesterol Lowering Drug Program Novel small molecule PCSK9 Inhibitor
Slide 11: Cholesterol Lowering Market
Cholesterol Lowering Market Population, Problem, Opportunity For personal use only 56 million 18.4 million between ages 40 and 75 Unable to achieve treatment eligible LDL-C target despite taking a statin1 62.6 million 27.4 million 1 in 5 patients Americans have high cholesterol1 statin intolerant3 t
Slide 12: Current PCSK9 Injectable Drugs
Current PCSK9 Injectable Drugs Expensive and Inconvenient For personal use only Effective when combined with statin treatment Expensive US$5,800 to US$6,500 per year Inconvenient for patient / poor compliance Expensive to manufacture Insurer / patient co-pay reluctance (US) • Patient convenience: on
Slide 13: Corporate
For personal use only Corporate ASX:NYR NYRADA INC (ASX:NYR) 13 AGM PRESENTATION
Slide 14: Financial Overview and Outlook
Financial Overview and Outlook For personal use only FY2023 Highlights and FY2024 Outlook Operating Results Summary • Resources: FY2023 (A$) FY2022 (A$) • Cash balance of $3.7M at end of June 2023 R&D Costs 6,411,264 1,835,072 • Cash balance of $2.3M at end of September Corporate and admin expenses
Slide 15: Summary & News Flow
Summary & News Flow For personal use only Brain Cholesterol Injury Corporate Lowering • Completion of candidate • Review of analogue • Ongoing cost GLP studies of NYX- library management initiatives BI03 • Low-cost background • Non dilutive funding • Expected works applications in US and commencemen
Slide 16: Thank you for your attention and your support!
For personal use only Thank you for your attention and your support! Questions? ASX:NYR NYRADA INC (ASX:NYR) 16 AGM PRESENTATION
Slide 17: References
References For personal use only 1 Brain Injury Alliance (Connecticut): http://www.biact.org/understanding-brain-injury/brain-injury-facts-statistics and US Centers for Disease Control and Prevention: https://www.cdc.gov/stroke/facts.htm 2 Wong ND et al. Prevalence of the American College of Cardiol
Slide 18: Brain Injury Solution and Cholesterol-Lowering Animation
For personal use only Brain Injury Solution Cholesterol-Lowering Animation Animation Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board. @nyrada_inc @nyrada_inc ASX:NYR info@nyrada.com www.nyrada.com NYRADA INC (ASX:NYR) 18 AGM PRESENTATION